Healthcare Realty Trust Announces New Executive Vice

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Healthcare Realty Trust Announces New Executive Vice President – Investments

NASHVILLE, Tenn., Dec. 30, 2016 (GLOBE NEWSWIRE) -- Healthcare Realty Trust Incorporated (NYSE: HR ) today announced that Robert E. Hull has been appointed as the Company’s Executive Vice President – Investments effective January 1, 2017. 

Mr. Hull is 44 years old and has been employed by the Company since 2004. He has served as a Senior Vice President since March 2011, managing the Company’s development and acquisition activity.  Prior to that, Mr. Hull served in various capacities on the Company’s investments team. Before joining the Company, Mr. Hull worked in the senior living and commercial banking industries.

Mr. Hull is assuming the position formerly held by Todd J. Meredith, who was appointed the Company’s President and Chief Executive Officer effective December 30, 2016. David R. Emery, the Company’s founding CEO, will serve as Executive Chairman of the Board of Directors.

Healthcare Realty Trust is a real estate investment trust that integrates owning, managing, financing and developing income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of September 30, 2016, the Company had investments of approximately $3.5 billion in 202 real estate properties in 29 states totaling approximately 14.5 million square feet. The Company provided leasing and property management services to approximately 10.1 million square feet nationwide.

In addition to the historical information contained within, the matters discussed in this press release may contain forward-looking statements that involve risks and uncertainties. These risks are discussed in filings with the Securities and Exchange Commission by Healthcare Realty Trust, including its Annual Report on Form 10-K for the year ended December 31, 2015 under the heading “Risk Factors,” and as updated in its Quarterly Reports on Form 10-Q filed thereafter.  Forward-looking statements represent the Company’s judgment as of the date of this release.  The Company disclaims any obligation to update forward-looking statements.

Carla Baca Director of Corporate Communications P: 615.269.8175

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring the $2.7 Billion Bid for Papa John’s: An Investment Insight

Updated Category News Views 229

Papa John’s $2.7 Billion Takeover Bid: Insights into Potential Value Recently, shares of Papa John’s International Inc (NASDAQ:PZZA) experienced a notable surge, leading to a halt in trading due to high volatility. This surprising movement came in light of credible reports suggesting a take-private cash offer of $65 per share from TriArtisan Capital Advisors, totaling...

Continue Reading
Key Highlights from Octopus Apollo VCT plc AGM Results

Updated Category News Views 105

Octopus Apollo VCT plc AGM Results Overview Octopus Apollo VCT plc recently conducted its Annual General Meeting (AGM), showcasing significant engagement from shareholders. The meeting aimed to discuss key resolutions impacting the future direction of the company. Voting Outcomes of the AGM The company disclosed that all resolutions were successfully passed during the...

Continue Reading
Carisma Therapeutics Showcases Strong Financial Performance

Updated Category News Views 104

Carisma Therapeutics Showcases Strong Financial Performance Carisma Therapeutics Inc. (NASDAQ: CARM), a clinical-stage biopharmaceutical company, recently released its financial performance for the third quarter of 2024. With a focus on developing innovative immunotherapies, Carisma provided insight into its ongoing projects. Key Developments and Milestones Carisma's...

Continue Reading
Epinephrine Market Growth Insights and Future Potential

Updated Category News Views 112

Overview of the Epinephrine Market The global epinephrine market is on a significant upswing, with recent evaluations estimating its value at USD 3.11 billion and a projected growth to approximately USD 6.39 billion within the next decade. As a critical hormone and neurotransmitter produced by the adrenal glands, epinephrine is essential in treating severe allergic...

Continue Reading
Canadian North Resources Achieves Major Milestones in Q2 2025

Updated Category News Views 183

Canadian North Resources Makes Significant Progress in Operational Strategy Highlights: Canadian North has expanded its bio-metallurgical programs significantly, achieving impressive nickel and cobalt extraction rates through innovative bio-leaching tests. The focus remains on extracting copper and other precious group elements (PGE) metals from the Ferguson Lake Project....

Continue Reading